84年鼠女哪年财运最旺,857comvvv色九欧美激情|85PO_87国产精品欲av国产av资源

[1]杜國慶,潘富偉,王玉鵬,等.強骨膠囊治療原發(fā)性骨質(zhì)疏松癥有效性和安全性的Meta分析[J].中醫(yī)正骨,2023,35(08):31-36.
　DU Guoqing,PAN Fuwei,WANG Yupeng,et al.Clinical outcomes and safety of Qianggu(強骨)capsules for treatment of primary osteoporosis:a meta-analysis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2023,35(08):31-36.
點擊復制

強骨膠囊治療原發(fā)性骨質(zhì)疏松癥有效性和安全性的Meta分析()
分享到：

《中醫(yī)正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第35卷
期數(shù):
2023年08期
頁碼:
31-36
欄目:
文獻研究
出版日期:
2023-08-20

文章信息/Info

Title:
Clinical outcomes and safety of Qianggu(強骨)capsules for treatment of primary osteoporosis:a meta-analysis
作者:
杜國慶1; 潘富偉1; 王玉鵬1; 石金玉1; 李正言1; 廉由之2; 陸潔航1; 章振林3; 詹紅生1
1.上海中醫(yī)藥大學附屬曙光醫(yī)院,上海 201203; 2.上海市寶山區(qū)中西醫(yī)結合醫(yī)院,上海 201999; 3.上海交通大學附屬第六人民醫(yī)院,上海 200233
Author(s):
DU Guoqing1; PAN Fuwei1; WANG Yupeng1; SHI Jinyu1; LI Zhengyan1; LIAN Youzhi2; LU Jiehang1; ZHANG Zhenlin3; ZHAN Hongsheng1
1.Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China2.Shanghai Baoshan Hospital of Integrated Traditional Chinese and Western Medicine,Shanghai 201999,China3.The Sixth People's Hospital Affiliated to Shanghai Jiao Tong University,Shanghai 200233,China
關鍵詞:
骨質(zhì)疏松; 強骨膠囊; 專題Meta分析; 有效性; 安全性
Keywords:
osteoporosis;  Qianggu capsule;  meta-analysis as topic;  efficacy;  safety
摘要:
目的:系統(tǒng)評價強骨膠囊治療原發(fā)性骨質(zhì)疏松癥(primary osteoporosis,POP)的有效性和安全性。方法:應用計算機檢索中國生物醫(yī)學文獻服務系統(tǒng)、萬方數(shù)據(jù)庫、中國知網(wǎng)、維普網(wǎng)、PubMed、Medline、Cochrane Library、Embase,篩選強骨膠囊治療POP的隨機對照試驗,試驗組采用強骨膠囊或強骨膠囊聯(lián)合常規(guī)療法治療,對照組采用常規(guī)療法治療。采用Cochrane偏倚風險評估工具對納入研究的文獻進行質(zhì)量評估,采用RevMan5.3軟件進行Meta分析。結果:共檢索到1434篇文獻,通過逐層篩選最終納入9篇文獻,均為中文文獻。Meta分析結果顯示,2組腰椎骨密度、臨床有效率、不良反應發(fā)生率比較,差異均無統(tǒng)計學意義[SMD=0.25,95%CI(-0.15,0.65),P=0.210; RR=1.10,95%CI(0.96,1.26),P=0.160; OR=1.53,95%CI(0.82,2.85),P=0.180],試驗組股骨頸骨密度高于對照組[SMD=0.44,95%CI(0.16,0.71),P=0.002],骨痛積分低于對照組[MD=-1.00,95%CI(-1.50,-0.51),P=0.000]。結論:現(xiàn)有的證據(jù)表明,單獨應用強骨膠囊或在常規(guī)療法基礎上聯(lián)合應用強骨膠囊治療POP,與單獨應用常規(guī)療法相比,在改善腰椎骨密度、臨床綜合療效和安全性方面作用相當,但前者在緩解骨痛、改善股骨頸骨密度方面優(yōu)于后者。
Abstract:
Objective:To systematically review the clinical outcomes and safety of Qianggu(強骨,QG)capsules in treatment of primary osteoporosis(POP).Methods:All the randomized controlled trial(RCT)articles about QG capsules for treatment of POP included from database establishing to September 30,2022 were retrieved from Chinese Biomedical Literature Service System,Wanfang Database,China National Knowledge Internet,Vip Database,PubMed,Medline,Cochrane Library and Embase through computer.The patients in experimental group were treated with oral application of QG capsules or combination of oral application of QG capsules with conventional therapies,while the ones in control group with conventional therapies alone.The methodological quality of researches in the articles was evaluated by using Cochrane bias risk assessment tools,and then a Meta-analysis was conducted by using RevMan5.3 software.Results:One thousand four hundred and thirty-four articles were searched out.After screening,9 Chinese articles(803 patients)were included in the final analysis,443 patients in experimental group and 360 ones in control group.The results of Meta-analysis revealed that there was no statistical difference in bone mineral density(BMD)of lumbar vertebrae,clinical efficacy rate and incidence rate of adverse reactions between the 2 groups(SMD=0.25,95%CI(-0.15,0.65),P=0.210; RR=1.10,95%CI(0.96,1.26),P=0.160; OR=1.53,95%CI(0.82,2.85),P=0.180),while the BMD of femoral neck was higher,the bone pain score was lower in experimental group compared to control group(SMD=0.44,95%CI(0.16,0.71),P=0.002; MD=-1.00,95%CI(-1.50,-0.51),P=0.000).Conclusion:Available evidences suggest that oral application of QG capsules alone or combination of oral application of QG capsules with conventional therapy is similar to conventional therapy alone in improving BMD of lumbar vertebrae,total clinical curative effects and safety in treatment of POP,however,the former is better than the latter in relieving bone pain and improving BMD of femoral neck.

參考文獻/References:

[1] 中華醫(yī)學會骨質(zhì)疏松和骨礦鹽疾病分會.中國骨質(zhì)疏松癥流行病學調(diào)查及“健康骨骼”專項行動結果發(fā)布[J].中華骨質(zhì)疏松和骨礦鹽疾病雜志,2019,12(4):317-318.
[2] 中華醫(yī)學會骨科學分會骨質(zhì)疏松學組.骨質(zhì)疏松性骨折診療指南[J].中華骨科雜志,2017,37(1):1-10.
[3] 中華醫(yī)學會骨質(zhì)疏松與骨礦鹽疾病分會.原發(fā)性骨質(zhì)疏松癥診療指南(2017)[J].中國骨質(zhì)疏松雜志,2019,25(3):281-309.
[4] 李梅,章振林,夏維波.骨質(zhì)疏松癥藥物治療的必由之路:長程序貫治療[J].中華骨質(zhì)疏松和骨礦鹽疾病雜志,2021,14(5):441-446.
[5] 中國中西醫(yī)結合學會骨傷科專業(yè)委員會.骨質(zhì)疏松癥中西醫(yī)結合診療指南[J].中華醫(yī)學雜志,2019,99(45):3524-3533.
[6] 黃委委,李哲,鄭旭耀,等.中成藥治療原發(fā)性骨質(zhì)疏松癥療效的系統(tǒng)評價[J].中國骨質(zhì)疏松雜志,2019,25(12):1798-1808.
[7] 《中成藥治療優(yōu)勢病種臨床應用指南》標準化項目組.中成藥治療骨質(zhì)疏松癥臨床應用指南(2021)[J].中國中西醫(yī)結合雜志,2022,42(4):393-404.
[8] 彭紅玲.強骨膠囊聯(lián)合唑來膦酸治療絕經(jīng)后骨質(zhì)疏松癥臨床研究[J].中西醫(yī)結合研究,2023,15(2):73-76.
[9] 趙光,徐則李,邵瓊星,等.利維愛及中藥補腎法防治絕經(jīng)后婦女骨質(zhì)疏松癥的臨床對比研究[J].中國骨質(zhì)疏松雜志,2004,10(3):337-339.
[10] 徐宏,任德華,梁柱,等.強骨膠囊合阿侖磷酸鈉治療絕經(jīng)后骨質(zhì)疏松癥的臨床研究[J].浙江中醫(yī)藥大學學報,2010,34(4):503-504.
[11] 王健,張維康,王朝暉.強骨膠囊治療絕經(jīng)后骨質(zhì)疏松癥28例[J].醫(yī)藥導報,2007,26(11):1325-1327.
[12] 阮祥燕,齊久梅,劉玉蘭,等.中藥對絕經(jīng)婦女股骨頸骨密度及股骨頸抗骨折能力的影響[J].中國骨質(zhì)疏松雜志,2006,12(2):181-184.
[13] 萬明,王康振,高大偉,等.鮭魚降鈣素聯(lián)合強骨膠囊對原發(fā)性骨質(zhì)疏松癥患者骨代謝的影響[J].中國藥業(yè),2018,27(15):61-63.
[14] 謝雁鳴,崔天紅,高蕊,等.強骨膠囊治療原發(fā)性骨質(zhì)疏松癥(腎陽虛證)的臨床研究[J].中藥新藥與臨床藥理,2000,11(4):197-201.
[15] 單碩,周光.強骨膠囊治療原發(fā)性骨質(zhì)疏松癥的臨床療效[J].西北藥學雜志,2006,21(4):177-178.
[16] 謝雁鳴,王和鳴,沈霖,等.強骨膠囊治療原發(fā)性骨質(zhì)疏松癥162例多中心隨機對照臨床研究[J].中醫(yī)雜志,2004,45(7):506-509.
[17] 夏文芳,陳璐璐.強骨膠囊與利塞膦酸鈉治療絕經(jīng)后骨質(zhì)疏松癥的對比研究[J].中國骨質(zhì)疏松雜志,2006,12(4):393-396.
[18] 夏維波,CYRUS COOPER,李梅,等.東方遇見西方:增齡性骨骼肌肉疾病的臨床實踐和策略[J].中華骨質(zhì)疏松和骨礦鹽疾病雜志,2019,12(5):432-455.
[19] 徐道明,許華寧,徐帥,等.原發(fā)性骨質(zhì)疏松癥慢性疼痛的康復治療進展[J].中國骨質(zhì)疏松雜志,2020,26(8):1197-1200.
[20] 何椋,李鳳珍,張志勇,等.中成藥治療原發(fā)性骨質(zhì)疏松癥系統(tǒng)評價的再評價[J].湖南中醫(yī)雜志,2022,38(7):110-114.
[21] 中華醫(yī)學會骨質(zhì)疏松與骨礦鹽疾病分會.原發(fā)性骨質(zhì)疏松癥診療指南(2022)[J].中華骨質(zhì)疏松和骨礦鹽疾病雜志,2022,15(6):573-611.

相似文獻/References:

[1]李林軍.應用膨脹式椎弓根螺釘內(nèi)固定治療合并骨質(zhì)疏松的 胸腰椎退行性疾病[J].中醫(yī)正骨,2015,27(08):49.
[2]韓艷,溫利平,劉娜,等.補腎活血方對去卵巢大鼠骨代謝及骨密度的影響[J].中醫(yī)正骨,2015,27(12):7.
　HAN Yan,WEN Liping,LIU Na,et al.Effect of Bushen Huoxue Fang(補腎活血方)on bone metabolism and bone mineral density in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(08):7.
[3]李學朋,朱立國.骨疏康膠囊對去卵巢大鼠骨小梁的影響[J].中醫(yī)正骨,2015,27(12):12.
　LI Xuepeng,ZHU Liguo.Effect of Gushukang Jiaonang(骨疏康膠囊)on bone trabecula in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(08):12.
[4]陳冠軍,陳揚,莊汝杰.可灌注骨水泥椎弓根螺釘系統(tǒng) 在老年腰椎疾患手術中的應用[J].中醫(yī)正骨,2015,27(02):40.
[5]王丹輝,賁越,韓梅.林蛙油治療絕經(jīng)后骨質(zhì)疏松癥的臨床研究[J].中醫(yī)正骨,2014,26(01):27.
　Wang Danhui*,Ben Yue,Han Mei..Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(08):27.
[6]黃建華,黃建武,李慧輝,等.加味左歸丸對絕經(jīng)后骨質(zhì)疏松癥肝腎不足證 患者骨密度的影響[J].中醫(yī)正骨,2013,25(11):19.
　Huang Jianhua*,Huang Jianwu,Li Huihui,et al.Effect of JIAWEI ZUOGUI pill on bone mineral density in postmenopausal osteoporosis patients with deficiency of liver and kidney[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(08):19.
[7]項旻,楊虹,林愛菊,等.絕經(jīng)后2型糖尿病患者骨質(zhì)疏松與血微量元素的關系研究[J].中醫(yī)正骨,2013,25(12):20.
　Xiang Min*,Yang Hong,Lin Aiju,et al.Clinical study on the relationship between osteoporosis and serum trace elements levels in postmenopausal women with type 2 diabetes[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(08):20.
[8]史曉林,李春雯,張志強.弱陽離子磁珠分離技術和基質(zhì)輔助激光解吸電離飛行時間質(zhì)譜技術在原發(fā)性Ⅰ型骨質(zhì)疏松癥血清標志蛋白篩選中的應用[J].中醫(yī)正骨,2014,26(03):5.
　Shi Xiaolin*,Li Chunwen,Zhang Zhiqiang..Application of magnetic beads based weak cation exchange separation technology and matrix-assisted laser desorption-ionization time of flight mass spectrometry technology in screening serum protein markers of primary type-Ⅰ osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(08):5.
[9]李明,徐明雄,馮左基,等.自擬壯骨方治療絕經(jīng)后骨質(zhì)疏松癥的療效及作用機制研究[J].中醫(yī)正骨,2014,26(09):21.
　Li Ming*,Xu Mingxiong,Feng Zuoji,et al.Study on the curative effect and mechanism of action of self-made ZHUANGGU decoction in treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(08):21.
[10]陳俊杰,李晴晴,夏瑢.脂代謝及血清內(nèi)脂素水平與絕經(jīng)后骨質(zhì)疏松癥的 相關性研究[J].中醫(yī)正骨,2012,24(04):16.
　CHEN Jun-jie*,LI Qing-qing,XIA Rong.*.Study on the correlations between the levels of lipid metabolism and serum visfatin and postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(08):16.

備注/Memo

備注/Memo:
基金項目:《中成藥治療優(yōu)勢病種臨床應用指南》標準化項目第三批優(yōu)勢病種指南子課題(SATCM-2015-BZ402-042); 全國名老中醫(yī)藥專家傳承工作室建設項目(國中醫(yī)藥人教函〔2022〕75號); 上海市2020年度“科技創(chuàng)新行動計劃”醫(yī)學創(chuàng)新研究專項項目(20MC1920600) 通訊作者:詹紅生 E-mail:[email protected] 章振林 E-mail:[email protected]
更新日期/Last Update: 1900-01-01